Healthcare entity
All 1 tracked stories fall under one category: market-trends. REL-1017 is most often covered alongside IB-Stim, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window.
Last mentioned: Mar 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. REL-1017 is most often covered alongside IB-Stim, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window. Source depth averages 3 original sources per story, versus 2.9 across the same-window beat baseline. We currently track 1 Healthcare story that mention REL-1017, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering REL-1017. Shared-story counts are live from our verified record — not editorial picks.
Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting a strategic shift toward late-stage clinical readouts and expanded commercial coverage for CNS therapies. Both companies are positioning themselves as leaders in non-traditional treatments for depression and pediatric pain, respectively.
Source: seekingalpha.com · insidermonkey.com
REL-1017 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
